OPKO Health, Inc. (NASDAQ:OPK) Given Consensus Recommendation of “Hold” by Brokerages

Shares of OPKO Health, Inc. (NASDAQ:OPKGet Rating) have received a consensus recommendation of “Hold” from the six brokerages that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and one has assigned a buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $6.33.

OPK has been the subject of a number of research analyst reports. Zacks Investment Research downgraded shares of OPKO Health from a “buy” rating to a “hold” rating and set a $6.00 price target for the company. in a report on Monday, January 24th. StockNews.com initiated coverage on shares of OPKO Health in a report on Thursday, March 31st. They issued a “sell” rating for the company. Barrington Research downgraded shares of OPKO Health from an “outperform” rating to a “market perform” rating in a report on Monday, January 24th. Piper Sandler upped their price target on shares of OPKO Health from $5.00 to $6.00 in a report on Tuesday, January 18th. Finally, TheStreet lowered shares of OPKO Health from a “c” rating to a “d+” rating in a research note on Friday, February 25th.

In other OPKO Health news, CEO Phillip Md Et Al Frost bought 350,000 shares of the company’s stock in a transaction dated Wednesday, January 26th. The shares were bought at an average price of $2.98 per share, for a total transaction of $1,043,000.00. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Insiders bought a total of 1,585,000 shares of company stock worth $4,849,400 in the last quarter. 41.47% of the stock is owned by corporate insiders.

Large investors have recently added to or reduced their stakes in the stock. Kestra Advisory Services LLC grew its holdings in OPKO Health by 37.4% during the fourth quarter. Kestra Advisory Services LLC now owns 41,336 shares of the biotechnology company’s stock valued at $199,000 after purchasing an additional 11,260 shares during the last quarter. Castle Rock Wealth Management LLC acquired a new position in OPKO Health during the fourth quarter valued at approximately $73,000. Metropolitan Life Insurance Co NY grew its holdings in OPKO Health by 9.9% during the third quarter. Metropolitan Life Insurance Co NY now owns 107,781 shares of the biotechnology company’s stock valued at $393,000 after purchasing an additional 9,693 shares during the last quarter. Rafferty Asset Management LLC grew its holdings in OPKO Health by 24.2% during the third quarter. Rafferty Asset Management LLC now owns 870,666 shares of the biotechnology company’s stock valued at $3,178,000 after purchasing an additional 169,452 shares during the last quarter. Finally, RK Asset Management LLC acquired a new position in OPKO Health during the fourth quarter valued at approximately $176,000. Hedge funds and other institutional investors own 26.34% of the company’s stock.

OPK stock opened at $3.21 on Wednesday. The company has a market capitalization of $2.19 billion, a P/E ratio of -64.19 and a beta of 1.86. The company has a 50-day simple moving average of $3.33 and a 200 day simple moving average of $3.77. OPKO Health has a fifty-two week low of $2.79 and a fifty-two week high of $5.25. The company has a quick ratio of 2.23, a current ratio of 2.49 and a debt-to-equity ratio of 0.11.

OPKO Health (NASDAQ:OPKGet Rating) last issued its quarterly earnings results on Thursday, February 24th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.03) by ($0.08). OPKO Health had a negative net margin of 1.70% and a negative return on equity of 1.75%. The business had revenue of $401.30 million during the quarter, compared to analyst estimates of $317.26 million. During the same period in the previous year, the company posted $0.05 earnings per share. OPKO Health’s revenue was down 18.9% compared to the same quarter last year. Equities analysts anticipate that OPKO Health will post -0.09 EPS for the current year.

OPKO Health Company Profile (Get Rating)

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services.

See Also

Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.